Method of treating a wound with acidified plasma or serum

Information

  • Patent Grant
  • 8017157
  • Patent Number
    8,017,157
  • Date Filed
    Tuesday, December 12, 2006
    18 years ago
  • Date Issued
    Tuesday, September 13, 2011
    13 years ago
Abstract
The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.
Description
TECHNICAL FIELD

The present invention relates to the use of blood plasma or serum as an agent for the treatment of wounds. More specifically, the present invention relates to a pharmaceutical composition for the treatment of wounds comprising blood plasma or serum and a method for treating wounds effectively by applying said composition to a wound site to normalize the tissue-environment around the wound site.


BACKGROUND ART

The early studies on the treatment of wounds have laid emphasis on a close examination of the functions of the cell stage, i.e., the functions of inflammatory cell and platelet [Allgower M. and Hulliger L., Surgery, 47, 603 (1960); Dicoreto P. E. and Browen-Pope D. F., Proc. Natl. Acad. Sci. USA, 80, 1919 (1983); and Houck J. C. et al., Biochem. Pharmacol., 17, 2081 (1968)].


Recently, growth factors to promote tissue growth have been used in the treatment of wounds such as chronic ulcers. The growth factors stimulate mitogenesis, which is the proliferation of cells such as fibroblast. The growth factors also stimulate angiogenesis, resulting in the ingrowth of new blood vessels. Moreover, the synthesis of collagen and extracellular matrix proteins is stimulated by the growth factors (L. Greenhalgh, J. Trauma 41:159 (1996)).


Cytokines have been found as growth factors associated with wound healing. Representative examples of such cytokines include basic fibrogrowth factor which is produced by keratinocytes and fibroblasts and promotes the growth of epithelial cells; platelet-derived growth factor (PDGF) which is produced by platelets and the endothelium and other cell types and promotes the abnormal proliferation of epithelial cells in association with epidermal growth factor (EGF); transforming growth factor-β (TGF-β) which is produced by fibroblasts and platelet and promotes the growth of connective tissue; epithelial cell-growth factor which is generated in salivary glands-stimulatory glands and promotes the proliferation of epithelial cells; fibroblast growth factor (FGF); and interleukin-1 which is produced by macrophages and epithelial cells and promotes the growth and mobility of epithelial cells. Becaplermin is a genetically engineered recombinant PDGF that is commercially available as an agent for the treatment of wounds in topical formulations by Johnson & Johnson under the trade name of Regranex®. EP 0 575 484 B1 discloses a pharmaceutical composition for the regeneration and repair of mammalian tissues which includes PDGF and dexamethasone. U.S. Pat. No. 5,981,606 discloses a pharmaceutical composition for treating wounds which includes TGF-β. WO 96/30038 discloses a pharmaceutical composition for wound healing which includes TGF-β and fibric acid together with antioxidants. U.S. Pat. No. 5,183,805 discloses a pharmaceutical composition having the effect of the regeneration of tissues which includes EGF. Japanese Patent No. 05070365 and U.S. Pat. No. 6,165,978 disclose wound healing formulation containing FGF.


Formulations utilizing hyaluronic acid as an active agent have also been reported as being useful in the treatment of skin ulcers (See U.S. Pat. No. 5,897,880). Formulations including sodium hyaluronate are marketed by LAM Pharmaceutical Corporation under the trade name of IPN Wound Gel®.


Topically applied fibronectin (glycoprotein found in blood plasma) has also been reported as being useful for increasing the rate of wound healing in corneal wounds (Nishida, Larch Opthalmology 101:1046 (1983)) and leg ulcers (Wysocki et al., Arch. Dermatol. 124:175 (1988)).


Although such treatments provide some patients with partial wound relief, they need long healing time and fail to exhibit optimum response to the treatment. As wounds, especially, chronic skin ulcers, become serious clinical problems, much effort has been made in finding effective treatments of the wounds. The underlying causes responsible for poor wound closure are complex and still poorly understood.


Therefore, it would be desirable to develop new and improved methods of treating wounds. Use of the present formulations either alone or in combination with various known therapeutic agents overcomes the limitations of the prior art.


SUMMARY OF THE INVENTION

The inventors of the present invention have surprisingly found that blood plasma or serum is highly effective in the treatment of wounds. We found that partial defect wounds could be healed in several days after application of the formulation containing blood plasma or serum according to the present invention. We more surprisingly found that large full defect wounds could be healed within several weeks (about 2 to 6 weeks) after application of the formulation containing blood plasma or serum according to the present invention. These findings represent very significant improvements in both response to treatment and healing time over conventional treatments or other therapeutics currently available or reported until now.


In one aspect, the present invention provides a pharmaceutical composition for wound healing which comprises a pharmaceutically effective amount of blood plasma or serum in combination with a pharmaceutically acceptable carrier.


In another aspect, the present invention provides a method of treating wounds of a subject which comprises applying a pharmaceutical composition comprising a pharmaceutically effective amount of blood plasma or serum to the wound of the subject in need of such treatment.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a protocol for treatment of chronic wounds according to one or more embodiments of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

The present invention generally relates to the use of blood plasma or serum which is useful for treating wounds. The blood plasma or serum used as an active agent in a pharmaceutical composition according to the present invention is highly effective in the treatment of wounds.


Wounds are damaged conditions of living bodies and encompasses cut or disrupted pathological conditions of tissues constituting the internal and external surface of the living body, for example skin, muscle, nervous tissue, bone, soft tissue, inner organs and vascular tissue. The exemplary wounds include, but are not limited to, contusion or bruise, non-healing traumatic wounds, tissue disruption by irradiation, abrasion, gangrene, laceration, avulsion, penetrated wound, gun shot wound, cutting, burn, frostbite, cutaneous ulcers, xeroderma, skin keratosis, breakage, rupture, dermatitis, dermatophytosis, surgical wounds, wounds caused by vascular disorders, corneal wounds, sores such as pressure sore and bed sore, diabetes and poor circulation-associated conditions diabetic skin erosion, chronic ulcers, suture site following plastic surgery, spinal traumatic wounds, gynecological wounds, chemical wounds and acne. Any damaged or injured part of the living body is within the definition of the wounds. In this respect, the composition comprising blood plasma or serum according to the present invention can be useful for the repair, replacement alleviation, acceleration, promotion, healing and/or curing of any damaged or injured tissue.


Blood plasma used as an active ingredient in the composition of the present invention typically indicates the straw-colored liquid portion remaining after the material bodies such as blood cells and cell fragments were separated out from the blood. The components of the plasma are well known in the art (Philip Westerman, Plasma Proteins, VII-1 to VIII-13, Sep. 17, 2002; and Wendy Y. Craig, et al., Plasma Proteins Pocket Guide, Foundation for Blood Research—each of which is incorporated by reference in its entirety). Serum is also well defined and generally called as blood plasma without fibrinogen and other clotting factors.


The source of blood plasma or serum used in the composition of the present invention includes humans and mammalian species, for example, primates, rodents and livestock such as sheep, goat, pig, horse, dog and cattle.


The blood plasma or serum used in the present invention can be readily obtained from the blood using conventional methods such as centrifugation, sedimentation and filtration. Centrifugation would be carried out under any conditions suitable to sediment blood cells and cell fragments, e.g., about 3,000 rpm for about 10 minutes. This condition is sufficient to remove substantially all cell fragments (platelets) as well as red and white blood cells.


The supernatant plasma can be easily separated from the centrifuged cells by standard techniques. Such separation can be achieved using filtration by passing the supernatant plasma through a suitable filter. The filters include a microporous membrane through which proteins are well penetrated.


Blood plasma or serum can be fresh liquid plasma or liquid preparation obtained by centrifugation or sedimentation of whole blood. In addition, blood plasma or serum are known to be reserved in various forms prior to use, including fresh-frozen preparation, cryoprecipitated preparation, lyophilized preparation or concentrated preparation. Such all forms of plasma or serum can be used for the present invention. The fresh-frozen plasma is obtained by centrifuging the blood at about 2,800 rpm for 15 minutes to separate out blood cells and cell fragments and freezing the remaining liquid portion at the temperature of from about −18° C. to −40° C. The centrifugation is carried out within six hours from blood collection. For the use, fresh-frozen plasma is thawed out in warm water at the temperature of from about 30° C. to 37° C.


The cryoprecipitated plasma is obtained by thawing out one unit of a fresh-frozen plasma at the temperature of 4° C. to form white precipitate (cold precipitated protein) (including large amounts of factors such as VIII:C, fibrinogen, XIII and fibronectin), isolating the formed precipitate and refreezing it at the temperature of from about −18° C. to −40° C. For its use, the cryoprecipitated preparation is thawed out by putting in a refrigerator at the temperature of from 1° C. to 6° C. overnight. It may be put in a water bath at the temperature of about 4° C. to melt down more rapidly. The concentrated plasma is obtained by separating plasma from whole blood, concentrating the separated plasma by mixing it with a thickener such as dextranomer, SEPHADEX, dextramine, polyacrylamide, BIO-GEL P, silica gel, zeolite, DEBRISAN, crosslinked agarose, starch and alginate gel and discarding the remaining thickener.


In one embodiment of the present invention, the blood plasma or serum used for the present invention can be those commercially available, for example, powdered preparations purchased from blood banks. These preparations are derived from units of human blood plasma, which have been tested to elicit no antigen-antibody reaction, for example, non-reactive for antibodies to hepatitis B surface antigen (HBsAg) and hepatitis C (HCV) antibody and negative for antibodies to HIV-1 and HIV-2 viruses. All units of blood plasma or serum used to prepare such preparations are certified free of pathogens.


To reduce the potential risk of transmission of infectious agents, the preparation may be treated with an organic solvent/detergent mixture, for example, tri(n-butyl)/phosphate/polysorbate 80 designed to inactivate enveloped viruses such as HIV, hepatitis B and HCV. The inactivation and removal of viruses can be enhanced by additionally performing a nanofiltration step.


In another embodiment, the plasma or serum preparation can be prepared through purification, i.e., using solvent detergent and nanofiltration, or pasteurization of a liquid plasma fraction. Alternatively, the whole blood may be purified. The resultant plasma or serum fraction can be powdered by heating, lyophilization or other suitable drying techniques. By way of example only, blood plasma is freeze-dried at the temperature of less than −40? for several days (e.g., about 7 days). Any conventional techniques and parameters known to those of skill in the art may be used.


In another further embodiment of the present invention, the blood plasma or serum may be in the form of sheet in addition to powder. The sheet is produced by putting the plasma or serum into an appropriate template and dehydrating it. In still another further embodiment, the sheet can be provided with mechanical strength and/or physical integrity by incorporating a thickening agent or carrier into the blood plasma or serum fraction.


In a preferred embodiment of the present invention, blood plasma or serum adjusted to acidic pH. We found that the acidified blood or serum has a superior wounds healing efficacy to weakly alkaline plasma or serum. Preferably, the plasma or serum has acidic pH values of from about 3.5 to 6.5. The blood plasma or serum can be acidified using pharmaceutically acceptable inorganic or organic acids. The examples of the pharmaceutically acceptable inorganic acid include, but are not limited to, hydrochloric acid, nitric acid, sulfuric acid and phosphoric acid. The examples of the pharmaceutically acceptable organic acids include, but are not limited to, formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, benzenesulfonic acid and p-toluenesulfonic acid.


According to the present invention, the blood plasma or serum in the form of liquid or powder can be applied directly onto the wound, i.e., sprinkled over the wound site. The plasma in the form of sheet may be applied over the wound site, which is then dressed suitably to protect the wound and prevent the healing effects of the active ingredient from diminishing. Any commercially available or conventional wound dressing may be used in the present invention. The examples of commercially available wound dressings include, but are not limited to, Compeel, Duoderm, Tagaderm and Opsite.


The composition containing a pharmaceutically effective amount of blood plasma or serum in combination with a pharmaceutically acceptable carrier can be formulated into a variety of forms by means known in the pharmaceutical art. The administration forms include, but are not limited to, conventional dosage forms of external preparation, e.g., liquid paints, sprays, lotions, creams, gels, pastes, liniments, ointments, aerosols, powders and transdermal absorbers. Actual methods for preparing administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 15th Edition, 1975, Mack Publishing Company, Easton, Pa. 18042 (Chapter 87: Blaug, Seymour), the contents of which are incorporated herein by reference.


In the external preparation of the present invention, suitable carriers can be chosen depending on the dosage forms and include, but are not limited to, hydrocarbons such as vaseline, liquid paraffin, and plasticized hydrocarbon gel (plastibase); animal and vegetable oils such as medium-chain fatty acid triglyceride, lard, hard fat, and cacao oil; higher fatty acid and alcohols and esters thereof such as stearic acid, cetanol, stearyl alcohol, and palmitic acid isopropyl; water-soluble bases such as Macrogol (polyethylene glycol), 1,3-butylene glycol, glycerol, gelatine, white sugar, and sugar alcohol; emulsifiers such as glycerine fatty acid ester, stearic acid polyoxyl, and polyoxyethylene/or curing castor oils; thickeners such as acrylic acid esters, and sodium alginates; propellants such as liquefied petroleum gas, and carbon dioxide; and preservatives such as paraoxybenzoic acid esters. The external preparation of the present invention can be prepared with the aforementioned carriers by methods well-known to those skilled in the art. In addition to said carriers, additives such as stabilizers, pigments, coloring agents, pH adjusting agents, diluents, surfactants, and antioxidants are, if necessary, used. The external preparation of the present invention can be applied to the tropical wound site by conventional methods.


The external preparation according to the present invention may be also used in adhesion onto a solid support such as a wound covering release layer. The adhesion is achieved by saturation of the solid support with the blood plasma or serum fraction, followed by dehydration of the fraction. In one embodiment of the present invention, the solid support is first coated with an adhesion layer to improve the adhesion of the blood plasma or serum to the solid support. Exemplary adhesion materials include polyacrylate and cyanoacrylate. As such formulation, there is provided a number of commercially available products, including bandage having non-adhesive wound-covering release layer in a perforated plastic film by Smith & Nephew Ltd., BAND-AID in thin strip, patch, spot and thermoplastic strip forms by Johnson & Johnson, CURITY and CURAD (“ouchless” type of bandage) by Kendall Co. (a division of Colgate-Palmolive Company), and STIK-TITE (elastic strip) by American White Cross Labs, Inc.


In one embodiment, the pharmaceutical composition according to the present invention can be formulated into a liquid paint preparation by mixing powdered plasma or serum with physiologic saline at a fixed ratio by volume and adjusting the pH value of the resulting mixture to the range of from 3.5 to 6.5. In another embodiment, time pharmaceutical composition according to the present invention can be formulated into an ointment preparation by mixing the powdered plasma or serum with a water-soluble ointment base and adding physiologic saline to the resulting mixture. Preferably, the pH value of the ointment is adjusted to the range of from 3.5 to 6.5.


According to the present invention, pharmaceutical carriers such as gels or microspheres may be used to promote the wound healing. A variety of microspheres of a polymer as carriers for one or more pharmaceutically or cosmetically active substances is described in U.S. Pat. No. 5,264,207, WO 2000/24378, WO96/13164 and WO 94/13333, the entire contents of which are incorporated herein by reference.


The pharmaceutical composition of the present invention can be used to treat a variety of wounds in mammalian animals. Especially, the composition of the present invention is effective for the treatment of non-healing ulcers, including those due to infection, malignancy, large vessel arterial insufficiency, small vessel arterial insufficiency, deep venous blockage or insufficiency, superficial venous insufficiency (varicose veins), lymphatic obstruction, intrinsic circulatory insufficiency, hematologic abnormalities, collagen vascular disorders, radiation dermatitis, trophic causes and the like.


A particular condition that can be treated with the pharmaceutical composition of the present invention includes radiation ulcers. Radiotherapy (for example, in the treatment of cancer) often leads to non-healing skin ulcers. Such ulcers do not respond well to conventional therapies as a result of poor circulation in the radiated tissue and are often treated with low intensity laser irradiation. Radiation ulcers respond well to treatment with the composition comprising the blood plasma or serum according to the present invention. In one embodiment of the present invention, 1 gm dose of the composition containing 5% by weight of blood plasma or serum is applied to a 5 cm2 surface area having a thickness of from about 1.5 to 2 mils.


The pharmaceutically effective amount of the blood plasma or serum contained in the composition of the present invention refers to an amount which normalizes various cell-activating substances and abnormal cells around the wound site and promotes the wound healing. As one or skill in the art will appreciate, the amount may vary depending on the wound type being treated, the wound site to be treated, the frequency and time of administration, the route and form of administration, the severity of the wound being treated, the kinds of vehicles, and other factors.


Generally, 2 to 5% by weight of powdered blood plasma or serum are administered per dose. The frequency of administration may range between twice daily and once per week. In a specific embodiment, full thickness defect wounds are treated with from 0.01 to 0.1 g/cm2 of the pharmaceutical composition of the present invention daily, preferably from 0.02 to 0.09 g/cm2, more preferably from 0.02 to 0.07 g/cm2.


An exemplary protocol 100 for the treatment of chronic non-healing wound is shown in FIG. 1. A defect wound is evaluated for determination of suitability for treatment with the active ingredient of the present invention, as shown in step 110 of FIG. 1. The treatment is appropriate for full thickness defect wounds such as diabetic ulcers, radiation ulcers, pressure sore, third degree burns and other tissue necrosis. The treatment is also appropriate for partial thickness defect wounds such as second degree burns, radiation dermatitis and tissue damaged during dermabrasion.


Once a defect wound is identified as suitable for the treatment according to the invention, the wound is cultured (step 120) to determine whether infection is present. The wound tissue is debrided, if needed. Stage 4 ulcers require debridement; some ulcers may also require deeper surgery. When the ulcers are filled with pus and necrotic debris, application of dextranomer beads or other hydrophilic polymers may hasten the tissue debridement without surgery. Conservative debridement of necrotic tissue with forceps and scissors should be instituted. Some debridement may be done by cleansing the wound with 1.5% hydrogen peroxide. Net dressings of water (especially whirlpool baths) will assist in debriding. The granulation that follows removal of necrotic tissue may be satisfactory for skin grafts to cover small areas.


When the culture is positive, the wound is treated for the infection (step 140). Wet dressing including an antibiotic (step 145) may be applied prior to blood plasma or serum treatment, or a formulation including powdered plasma or serum in combination with antibiotic is applied (step 148). Exemplary antibiotics include, but are not limited to, penicillinase-resistant penicillin or cephalosporin.


Where the culture is negative (step 150), no antibiotics need to be applied, and the wound is treated with the powdered plasma or serum of the invention (step 155).


The powdered plasma or serum is applied to the wound in any of a variety of formulations disclosed herein, and the wound is dressed with conventional wound dressings, such as Compeel, Duoderm, Tagaderm or Opsite wound dressings. Depending on the amount of blood plasma or serum to be administered and the desired release profile of the blood plasma or serum from the pharmaceutical carrier, dressings are changed at intervals ranged between 1 day and 5 days, and may be changed at intervals of 3-4 days. Depending on the extent of damage to the underlying tissue, healing of partial thickness defect wounds is observed in as little as 4 days and of full thickness defect wounds in as little as 2-4 weeks.


The present invention will be more specifically illustrated by the following examples. The following examples are provided to illustrate the present invention, but are not intended to be limited.


EXAMPLES
Example 1
Preparation of Blood Plasma in Liquid Phase

A human fresh-frozen blood plasma preparation (Central Blood Center of The Republic of Korea National Red Cross, Seoul, Korea), which was certified negative for pathogens including HIV, HCV and hepatitis B, was thawed out at the temperature of 30° C. and then mixed with physiologic saline at the ratio by volume of 10:1. The pH of the resulting mixture was adjusted to the value of 5.5 by adding 1N HC1 or 1N NaOH with stirring to afford the desired liquid plasma. The pH value was measured using the Orion pH Meter.


The remaining blood plasma preparation was cryopreserved in lyophilization bottles, vials, containers or trays, or in other storage bottles.


Example 2
Preparation of Lyophilized Blood Plasma in Powder Form

A human fresh-frozen blood plasma preparation (Central Blood Center of The Republic of Korea National Red Cross, Seoul, Korea), which was certified negative for pathogens including HIV, HCV and hepatitis B, was thawed out at the temperature of 30? . . . 500 ml of the resulting liquid blood plasma was placed into a lyophilization bottle and then frozen at the temperature of −80° C. (Deep Freezer, Forma Science, Inc., Ohio, USA) for 8 hours. The frozen bottle was mounted on a freeze drying/lyophilization system (Labconco Corporation, Kansas City, Mo., USA) and lyophilized at the temperature of −48° C. for 7 days. All processes were under sterile conditions. 500 ml of liquid blood plasma provides approximately 30 g of lyophilized plasma powder.


Example 3
Preparation of Ointment Formulation

5 g of plasma powder prepared as described in Example 2 was mixed with 95 g of water-soluble ointment base (SAM-A base, SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea).


A proper quantity of physiologic saline was added to the resulting mixture with stirring to afford the desired ointment. The ointment base consists of 38 mg of sperm wax, 116 mg of stearyl alcohol, 38 mg of polyethylene glycol 4000, 192 mg of concentrated glycerine, 23 mg of cetanol, proper quantity of purified water, 9 mg of sodium lauryl sulfate, 0.87 mg of paraoxybenzoic acid ethyl and 0.12 mg of paraoxybenzoic acid butyl, based on 1 g of the base.


Example 4
Preparation of ph-Adjusted Ointment

5 g of plasma powder prepared as described in Example 2 was mixed with 95 g of a water-soluble ointment base (SAM-A base, SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea). A proper quantity of physiologic saline was added to the resulting mixture to produce an ointment. 1N HC1 or 1N NaOH was added to the ointment with stirring to afford the ointment having the pH value of 5.5, which was determined using the Orion pH Meter.


Example 5
Preparation of Lyophilized Blood Plasma in Powder Form

500 ml of fetal bovine serum (FBS, Biofluids, Inc., Rockville, Md., USA) having not greater than 0.1 ng/mg of endotoxin capacity and not greater than 30 ng/100 ml of hemoglobin capacity was placed into a lyophilization bottle and then frozen at the temperature of −80° C. (Deep Freezer, Forma Science, Inc., Ohio, USA) for 6 hours. The frozen bottle was mounted on a freeze drying/lyophilization system (Labconco Corporation, Kansas City, Mo., USA) and lyophilized at the temperature of −48° C. for 7 days to afford the desired lyophilized plasma powder. All processes were under sterile conditions.


Example 6
Preparation of Ointment

5 g of plasma powder prepared as described in Example 5 was mixed with 95 g of a water-soluble ointment base (SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea). A proper quantity of physiologic saline was added to the resulting mixture to produce an ointment. 1N HC1 or 1N NaOH was added to the ointment with stirring to afford the desired ointment having a pH 5.5, which was determined using the Orion pH Meter.


Example 7
Preparation of Gel

5 parts by weight of plasma powder prepared as described in Example 2 was mixed with 95 parts by weight of an emulsion, which consists of 38 mg of Carbopol ETD 2020, 116 mg of glycerin, 38 mg of propylene glycol, 192 mg of triethanolamine and a proper quantity of purified water, to afford a clear gel with pHs 5.8-6.0. Carbopol ETD 2020 is the mixture of acrylates and C10-30 alkyl acrylate crosspolymer.


Experimental Example 1
Wound-healing Effect of Human Liquid Blood Plasma

The human liquid blood plasma according to the present invention as prepared in Example 1 was applied to a full thickness defect wound to histologically study whether it promotes the formation of granulation tissue on the wound. Ten adult white Sprague-Dawley rats weighing 300-350 mg were used in this experiment.


The animal abdomen was completely shaved and subjected to full thickness defect wound with the size of 10 mm×10 mm. Two wounds were created near both upper limbs, respectively. Likewise, two wounds were created near both lower limbs, respectively. Over each of the two wounds on left side upper and lower limbs, two layers of gauze with the size of 10 mm×10 mm wetted by 0.3 ml of liquid blood plasma having a pH 5.5 was applied. As control, over each of the two wounds on right side upper and lower limbs, two levers of gauze with the size of 10 mm×10 mm wetted by 0.3 mol of distilled water was applied. Then a dressing film (Tagaderm, 3M) was placed over that, which was sewed up on all four sides by 5/0 nylon suture so as not to be detached over the experimental period.


On day 7 after the experiment, wound tissues were taken. Biopsies were 10% neutral buffered formalin fixed for 24 hours and paraffin embedded. The paraffin-embedded biopsies were dissected 4 um in thickness. Sections were stained with hematoxyline-eosine and Masson's trichrome for the visualization of connective tissues. The width of the created granulation tissue was measured from microscopic observation at a magnification of 100× using image analysis program (Image-Pro version 3.0, Microsoft).


The thickness of the granulation tissue layer with only newly formed blood vessels was also measured. The newly formed blood vessels are those that grow from the basement of the tissue to the upper layer, i.e., longitudinally dissected blood vessels in the tissue.


In the case where sections were not of uniform thickness, those having the thickness in the middle of values list were taken. The values obtained were statistically analyzed by Student t-test.


As results, the granulation tissues of the test group were significantly thicker than those of the control group.


The trichrome staining revealed that the test group has very densely deposited collagen fibers, whereas the control group shows loose distribution of thin collagen fibers. In the test group, new blood vessels of the granulation tissues were created densely between the basement and the upper layer, indicating that the granulation tissues were grown actively. As contrast, the control group shows that a few of new blood vessels were found only at the basement of the granulation tissues, indicating that active development of the granulation tissues has not yet been initiated. The thickness of the granulation tissues was measured under the microscope using 40× magnification. The results were statistically analyzed using Student's t-test (p<0.05). The test group showed 168.62 μm±16.06 which was significantly different from the control group of 59.44 μm±14.42 (p<0.01). The values were expressed as means+/− standard deviation (SD).


Experimental Example 2
Wound-Healing Effect of Human Blood Plasma Powder

The human blood plasma powder according to the present invention as prepared in Example 2 was applied to a full thickness defect wound to histologically study whether it promotes the formation of granulation tissue on the wound.


In accordance with the same manner as described in the above Experimental Example 1, ten adult white rats were subjected to full thickness defect wound. The two wounds on left side upper and lower limbs were treated with 0.05 g of the human blood plasma powder. As control, the right side two wounds were not treated. Then a dressing film (Tagaderm, 3M) was placed over the gauzed area, which was sewed up on all four sides by 5/0 nylon suture so as not to be detached over the experimental period.


On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was histologically viewed and measured in accordance with the same manner as described in the above Experimental Example 1. As results, the granulation tissues of the test group were significantly thicker than those of the control group.


In the trichrome staining, whereas the control group showed loosely distributed thin collagen fibers, the test group showed dense deposited collagen fibers. The development of new blood vessels in the granulation tissues of the test group was similar to that of the above Experimental Example 1 in that they were created densely between the basement and the upper layer. The thickness of the granulation tissues was measured under the microscope using 100× magnification. The results were statistically analyzed using Student's t-test (p<0.05). The test group showed 151.62 μm±14.24 which was significantly different from the control group of 44.24 μm±14.32 (p<0.01). The values were expressed as means+/− standard deviation (SD).


Experimental Example 3
Wound-Healing Effect of Human Blood Plasma-Containing Ointment

The ointment containing human blood plasma according to the present invention as prepared in Example 3 was applied to a full thickness defect wound to histologically study whether it promotes the formation of granulation tissue on the wound.


In accordance with the same manner as described in the above Experimental Example 1, ten adult white rats were subjected to full thickness defect wound. The two wounds on left side upper and lower limbs were treated with 0.3 g of the ointment of the present invention. As control, the right side two wounds were treated with 0.3 g of SAM-A base (SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea). Then a dressing film (Tagaderm, 3M) was placed over the gauzed area, which was sewed up on all four sides by 5/0 nylon suture so as not to be detached over the experimental period.


On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was histologically viewed and measured in accordance with the same manner as described in the above Experimental Example 1. As results, the granulation tissues of the test group were significantly thicker than those of the control group.


In the trichrome staining, whereas the control group showed loosely distributed thin collagen fibers, the test group showed dense deposited collagen fibers. The development of new blood vessels in the granulation tissues of the test group was similar to that of the above Experimental Example 1 in that they were created densely between the basement and the upper layer.


The thickness of the granulation tissues was measured under the microscope using 100× magnification. The results were statistically analyzed using Student's t-test (p<0.05). The test group showed 164.50 μm±17.64 which was significantly different from the control group of 54.54 μm±10.02 (p<0.01). The values were expressed as means+/− standard deviation (SD).


Experimental Examples 4 and 5
Wound-Healing Effect of Fetal Bovine Serum-Containing Ointment and Powder

These experiments were conduced to study the wound-healing effect of blood plasma derived from non-human animals. The abdomens of twenty adult white rats were subjected to full thickness defect wound. In accordance with the same manner as described in the above Experimental Example 2, the first group of animals was treated with fetal bovine serum powder prepared in the above Example 5. In accordance with the same manner as described in the above Experimental Example 3, the second group of 10 animals was treated with fetal bovine serum powder prepared in the above Example 6.


On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was histologically viewed and measured in accordance with the same manner as described in the above Experimental Examples 2 and 3. As results, the granulation tissues of the test group were significantly thicker than those of the control group.


In the trichrome staining, whereas the control group showed loosely distributed thin collagen fibers, the test group showed dense deposited collagen fibers. The development of new blood vessels in the granulation tissues of the test group was similar to that of the above Experimental Examples 2 and 3 in that they were created densely between the basement and the upper layer.


The thickness of the granulation tissues was measured under the microscope using 100× magnification. The results were statistically analyzed using Student's t-test (p<0.05). For the fetal bovine serum powder, the test group showed 152.62 μm±20.86 which was significantly different from the control group of 41.20 μm±7.44 (p<0.01).


For the fetal bovine serum-containing ointment, the test group showed 168.62 μm±19.26 which was significantly different from the control group of 58.62 Zμm±7.62 (p<0.01).


The values were expressed as means+/− standard deviation (SD).


Experimental Example 6
Comparison of Wound-Healing Effects Between Fetal Bovine Serum-Containing Ointment and PDGF Ointment

In this experiment, the wound-healing effect of the fetal bovine serum-containing ointment prepared in the above Example 6 according to the present invention was compared to that of the Regranex® (PDGF ointment, Johnson & Johnson) which was first approved as a wound-healing agent by the FDA.


Ten adult white rats were subjected to full thickness defect wound in accordance with the same manner as described in the above Experimental Example 3 except that two full thickness defect wounds were additionally formed along the middle line of the abdomen. While the two wounds on left side upper and lower limbs were treated with 0.3 g of the ointment of the present invention, the two wounds on right side upper and lower limbs were treated with 0.3 g of Regranex®. As control, the two wounds on the middle line of the abdomen were treated with SAM-A base (SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea)


On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was histologically viewed and measured in accordance with the same manner as described in the above Experimental Example 2. As results, the granulation tissues of the Regranex®-treated group were thicker than those of the control group but were thinner than those of the test group. Moreover, the granulation tissues of the Regranex®-treated group were not dense.


The trichrome staining revealed that the Regranex®-group generated only few collagen fibers, which were not different from the control group. As contrast, the test group showed densely deposited collagen fibers which were as thick as those of normal dermis and were evenly distributed. For the new blood vessels of the granulation tissues, the Regranex®-treated group showed only few longitudinally growing blood vessels. As contrast, the test group showed new blood vessels of the granulation tissues which were densely created between the basement and the upper layer.


The thickness of the granulation tissues was measured under the microscope using 200× magnification. The results were statistically analyzed using Student's t-test (p<0.05). The test group showed 168.62 μm±13.41 which was significantly different from the Regranex®-treated group of 81.82 μm±18.01 (p<0.01). The values were expressed as means+/− standard deviation (SD).


Experimental Example 7
Comparison of Wound-Healing Effects Between Human Blood Plasma-Containing Ointment and PDGF Ointment

In this experiment, the wound-healing effect of the human blood plasma-containing ointment prepared in the above Example 3 according to the present invention was compared to that of the Regranex® (PDGF ointment, Johnson & Johnson). The abdomen of an adult white rat was subjected to four full thickness defect wounds. As control, the first upper wound was not treated with any agent but was well protected. The second wound was treated with 0.3 g of Regranex®. Each of the third and fourth wounds was treated with 0.3 g of the human blood plasma-ontaining ointment.


The third and fourth wounds treated with the human blood Plasma-containing ointment were even more quickly healed compared to the first non-treated wound and the second Regranex®-treated wound. FIG. 7 shows photographs of the wound sites on days 4 and 11 after the initiation of treatment. It can be seen that the plasma-treated wounds (marked as Healadex) showed onset of healing by the 4th day and that by the 11th day, the wounds were almost healed.


Experimental Example 8

This experiment demonstrates the healing effect of the FBS-containing ointment as prepared in the above Example 6 according to the present invention on large wounds. The second-degree burn (partial thickness defect wound) was treated with the FBS-containing ointment of the present invention. FIG. 8 showed the extent of healing on days 1, 2 and 4 after treatment. The complete wound closure was viewed on day 4 after treatment.

Claims
  • 1. A method of treating a wound comprising applying to the wound a pharmaceutically effective amount of a composition consisting essentially of blood plasma or blood serum having a pH of 3.5 to 6.6.
  • 2. The method of claim 1, wherein said composition consists essentially of blood plasma having a pH of 3.5 to 6.6.
  • 3. The method of claim 1, wherein said blood plasma or blood serum is derived from livestock.
  • 4. The method of claim 1, wherein said composition is applied to the wound in an amount of 0.01 to 0.1 g/cm2.
  • 5. The method of claim 1, wherein the composition is topically applied.
  • 6. The method of claim 1, wherein the composition is in the form of a cream, an ointment, a gel, or a patch.
  • 7. The method of claim 1, wherein the wound is a contusion, a bruise, a non-healing traumatic wound, a disruption by irradiation, an abrasion, a bone gangrene, laceration, an avulsion, a penetrated wound, a gun shot wound, a cut, a burn, a cold sore, a cutaneous ulcer, xeroderma, skin kefatosis, a break, a rupture, dermatitis, pain by dermatophyte, a wound by surgery, a wound by vascular disorder, a corneal wound, a pressure sore, a bed sore, a wound associated with diabetes, a chronic ulcer, a suture site, a spinal traumatic wound, a gynecological wound, a chemical wound or acne.
  • 8. The method of claim 1, wherein wound associated with diabetes is caused by diabetic cutaneous disorder or poor circulation.
  • 9. The method of claim 1, wherein the wound is a full thickness defect wound.
Priority Claims (1)
Number Date Country Kind
10-2003-00922 May 2003 KR national
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of application Ser. No. 10/508,841, filed Sep. 21, 2004, now abandoned which claims priority to PCT/KR03/00922 filed May 9, 2004.

US Referenced Citations (170)
Number Name Date Kind
4006220 Gottlieb Feb 1977 A
4061731 Gottlieb Dec 1977 A
4141973 Balazs Feb 1979 A
4427650 Stroetmann Jan 1984 A
4427651 Stroetmann Jan 1984 A
4659572 Murray Apr 1987 A
4769234 Pines et al. Sep 1988 A
4808576 Schultz et al. Feb 1989 A
4842305 Kistenich et al. Jun 1989 A
4851521 Della Valle et al. Jul 1989 A
4863897 Dede et al. Sep 1989 A
4920104 DeVore et al. Apr 1990 A
4937254 Sheffield et al. Jun 1990 A
4937270 Hamilton et al. Jun 1990 A
5017229 Burns et al. May 1991 A
5017900 Ura et al. May 1991 A
5095037 Iwamitsu et al. Mar 1992 A
5149691 Rutherford Sep 1992 A
5165938 Knighton Nov 1992 A
5166331 Della Valle et al. Nov 1992 A
5183805 Lee et al. Feb 1993 A
5190759 Lindblad et al. Mar 1993 A
5196185 Silver et al. Mar 1993 A
5209724 Dhaliwal et al. May 1993 A
5234914 Gallina Aug 1993 A
5236906 Yamamoto Aug 1993 A
5356683 Egolf et al. Oct 1994 A
5358973 Lindblad et al. Oct 1994 A
5376365 Dikstein Dec 1994 A
5376636 Rutherford et al. Dec 1994 A
5409904 Hecht et al. Apr 1995 A
5432167 Brismar Jul 1995 A
5510418 Rhee et al. Apr 1996 A
5514657 Shoshan et al. May 1996 A
5520926 Ferguson May 1996 A
5529987 Gallina Jun 1996 A
5532221 Huang et al. Jul 1996 A
5550112 Gallina Aug 1996 A
5583120 Gallina Dec 1996 A
5585007 Antanavich et al. Dec 1996 A
5591444 Boss, Jr. Jan 1997 A
5604200 Taylor-McCord Feb 1997 A
5614506 Falk et al. Mar 1997 A
5624915 Gallina Apr 1997 A
5631011 Wadstrom May 1997 A
5631241 Della Valle et al. May 1997 A
5631242 Gallina May 1997 A
5639738 Falk et al. Jun 1997 A
5641483 Beaulieu Jun 1997 A
5663160 Meybeck et al. Sep 1997 A
5681825 Lindqvist et al. Oct 1997 A
5728391 Ikeya et al. Mar 1998 A
5731298 Reinmuller Mar 1998 A
5733545 Hood, III Mar 1998 A
5744449 Lipps et al. Apr 1998 A
5763399 Lee Jun 1998 A
5792753 Falk et al. Aug 1998 A
5811410 Falk et al. Sep 1998 A
5817642 Falk et al. Oct 1998 A
5824658 Falk et al. Oct 1998 A
5827834 Falk et al. Oct 1998 A
5830882 Falk et al. Nov 1998 A
5834444 Falk et al. Nov 1998 A
5852002 Falk et al. Dec 1998 A
5866554 Shalaby et al. Feb 1999 A
5897880 Drizen et al. Apr 1999 A
5914322 Falk et al. Jun 1999 A
5925656 Kallam et al. Jul 1999 A
5942498 Falk et al. Aug 1999 A
5962433 Falk et al. Oct 1999 A
5972906 Asculai et al. Oct 1999 A
5977088 Harper et al. Nov 1999 A
5981606 Martin Nov 1999 A
5985850 Falk et al. Nov 1999 A
5990095 Falk et al. Nov 1999 A
6010692 Goldberg et al. Jan 2000 A
6022866 Falk et al. Feb 2000 A
6037331 Shalaby et al. Mar 2000 A
6048844 Falk et al. Apr 2000 A
6063406 Hornack May 2000 A
6069135 Falk et al. May 2000 A
6086907 Goldberg et al. Jul 2000 A
6087344 Falk et al. Jul 2000 A
6096727 Kuo et al. Aug 2000 A
6103704 Falk et al. Aug 2000 A
6114314 Falk et al. Sep 2000 A
6120804 Drizen et al. Sep 2000 A
6136793 Falk et al. Oct 2000 A
6140312 Falk et al. Oct 2000 A
6147059 Falk et al. Nov 2000 A
6165978 Rodgers et al. Dec 2000 A
6171611 Picciano Jan 2001 B1
6194392 Falk et al. Feb 2001 B1
6218373 Falk et al. Apr 2001 B1
6232303 Callegaro et al. May 2001 B1
6251876 Bellini et al. Jun 2001 B1
6262020 Lezdey et al. Jul 2001 B1
6271216 Mello et al. Aug 2001 B1
6284285 Weis-Fogh Sep 2001 B1
6294202 Burns et al. Sep 2001 B1
6335034 Drizen et al. Jan 2002 B1
6387407 Drizen et al. May 2002 B1
6387413 Miyata et al. May 2002 B1
6495148 Abbiati Dec 2002 B1
6509322 Benedetti et al. Jan 2003 B2
6521223 Calias et al. Feb 2003 B1
6541460 Petito Apr 2003 B2
6573249 Lezdey et al. Jun 2003 B2
6596703 Seed et al. Jul 2003 B1
6627620 Nielsen Sep 2003 B1
6635267 Miyoshi et al. Oct 2003 B1
6699471 Radice et al. Mar 2004 B2
6723345 Drizen et al. Apr 2004 B2
6828308 Mastradonato et al. Dec 2004 B2
6838448 Ponzin Jan 2005 B2
6924273 Pierce Aug 2005 B2
7015198 Orentreich et al. Mar 2006 B1
7132412 Petrigini et al. Nov 2006 B2
7157080 Radice et al. Jan 2007 B2
20020025921 Petito et al. Feb 2002 A1
20020068716 Melmed et al. Jun 2002 A1
20020151466 Hubbard et al. Oct 2002 A1
20020173485 Mastradonato et al. Nov 2002 A1
20030007957 Britton et al. Jan 2003 A1
20030124197 Signore et al. Jul 2003 A1
20030147830 Phillips et al. Aug 2003 A1
20030152639 Britton et al. Aug 2003 A1
20030180390 Keum et al. Sep 2003 A1
20030187381 Greenawalt et al. Oct 2003 A1
20030211166 Yamamoto et al. Nov 2003 A1
20030212005 Petitio et al. Nov 2003 A1
20040019011 Falk et al. Jan 2004 A1
20040092482 Gupta May 2004 A1
20040180622 Godfrey Sep 2004 A1
20040192643 Pressato et al. Sep 2004 A1
20040197319 Harch et al. Oct 2004 A1
20040242535 Court et al. Dec 2004 A1
20040254143 Mastradonato et al. Dec 2004 A1
20050107330 Greve et al. May 2005 A1
20050129622 Rault et al. Jun 2005 A1
20050136122 Sadozai et al. Jun 2005 A1
20050136126 Keum et al. Jun 2005 A1
20050142161 Freeman et al. Jun 2005 A1
20050142208 Yoo et al. Jun 2005 A1
20050147679 Petito et al. Jul 2005 A1
20050180938 Novelli Aug 2005 A1
20050181025 Velebny et al. Aug 2005 A1
20050182022 Pierce Aug 2005 A1
20050191286 Gandy Sep 2005 A1
20050220882 Pritchard et al. Oct 2005 A1
20050234011 Mazzone et al. Oct 2005 A1
20050234013 Parsons Oct 2005 A1
20050267068 Back et al. Dec 2005 A1
20050272695 Bach et al. Dec 2005 A1
20060040895 Thacker Feb 2006 A1
20060069064 Khaldoyanidi Mar 2006 A1
20060105991 Ishikawa et al. May 2006 A1
20060121002 Rolland et al. Jun 2006 A1
20060122147 Wohlrab Jun 2006 A1
20060147393 Macchi Jul 2006 A1
20060153893 Matsuno et al. Jul 2006 A1
20060188578 Fernandez et al. Aug 2006 A1
20060194759 Eidelson Aug 2006 A1
20060258560 Yang et al. Nov 2006 A1
20060293257 Rosenbloom Dec 2006 A1
20070003505 Carey Jan 2007 A1
20070048387 Edwards et al. Mar 2007 A1
20070048391 Keum et al. Mar 2007 A1
20070059377 Freddo et al. Mar 2007 A1
20070087061 Drake et al. Apr 2007 A1
Foreign Referenced Citations (16)
Number Date Country
1156042 Aug 1997 CN
1270812 Oct 2000 CN
0493985 Jul 1992 EP
0497724 Aug 1992 EP
2770779 May 1999 FR
03-240738 Oct 1991 JP
07-267992 Oct 1995 JP
2082415 Jun 1997 RU
WO 8603122 Jun 1986 WO
9308811 May 1993 WO
WO 9422470 Oct 1994 WO
9619982 Jul 1996 WO
9630038 Oct 1996 WO
0230432 Apr 2002 WO
03094937 Nov 2003 WO
2004028404 Apr 2004 WO
Related Publications (1)
Number Date Country
20070148142 A1 Jun 2007 US
Continuations (1)
Number Date Country
Parent 10508841 Sep 2004 US
Child 11638056 US